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Ryanodine receptors (RyRs) are calcium release
channels located in the membrane of the endo-
plasmic and sarcoplasmic reticulum and play a ma-
jor role in muscle excitation-contraction coupling.
The cardiac isoform (RyR2) is the target for >150
mutations that cause catecholaminergic polymor-
phic ventricular tachycardia (CPVT) and other condi-
tions. Here, we present the crystal structure of the
N-terminal region of RyR2 (1–547), an area encom-
passing 29 distinct disease mutations. The protein
folds up in three individual domains, which are
held together via a central chloride anion that
shields repulsive positive charges. Several disease
mutant versions of the construct drastically destabi-
lize the protein. The R420Q disease mutant causes
CPVT and ablates chloride binding. The mutation
results in reorientations of the first two domains
relative to the third domain. These conformational
changes likely activate the channel by destabilizing
intersubunit interactions that are disrupted upon
channel opening.
INTRODUCTION
The ryanodine receptor (RyR) is a Ca2+ release channel found in
the membranes of the endoplasmic and sarcoplasmic reticulum
(ER/SR) (Van Petegem, 2012). Three different isoforms have
been found in mammalian organisms (RyR1–RyR3) (Hakamata
et al., 1992; Otsu et al., 1990; Takeshima et al., 1989), which
share65% pairwise sequence identity. Many of these isoforms
are expressed in different tissues, but the RyR2 isoform is mainly
expressed in the heart, where it is directly involved in the
contraction of cardiac muscle. It can be activated by rises in
cytoplasmic or luminal Ca2+, thereby releasing Ca2+ from the
SR into the cytosol.
Several high- and low-resolution studies have shed light on
the RyR structure (Kimlicka and Van Petegem, 2011). Cryo-
electron microscopy (cryo-EM) reconstructions show that the1440 Structure 21, 1440–1449, August 6, 2013 ª2013 Elsevier Ltd AlRyR has an overall mushroom shape (Ludtke et al., 2005;
Samso´ et al., 2005, 2009), with the stalk crossing the membrane
and the large cap located entirely in the cytosol. In addition,
several crystal structures of cytoplasmic domains or domain
clusters have been solved (Amador et al., 2009; Kimlicka
et al., 2013; Lobo et al., 2011; Lobo and Van Petegem, 2009;
Sharma et al., 2012; Tung et al., 2010; Yuchi et al., 2012). In
some cases, these can be docked reliably into the available
cryo-EM maps. This includes the N-terminal region of RyR1,
an area consisting of three domains (A, B, and C), which was
found to be located near the fourfold symmetry axis, forming
a cytoplasmic vestibule (Tung et al., 2010). Opening and closing
of RyRs results in many allosteric motions within the cyto-
plasmic cap (Samso´ et al., 2009). This includes movements in
the N-terminal region, and an attractive model suggests that
intersubunit contacts, mediated by domains A and B from
neighboring subunits, can be disrupted upon channel opening
(Kimlicka et al., 2013). As such, it appears that the N-terminal
region acts as a ‘‘brake’’ on channel opening.
RyRs are targets for hundreds of disease mutations. Muta-
tions in RyR2 are mostly associated with catecholaminergic
polymorphic ventricular tachycardia (CPVT), a condition that
leads to triggered cardiac arrhythmias and can result in sudden
cardiac death (Priori et al., 2001). In addition, some mutations
are associated with arrhythmogenic right ventricular dysplasia
type 2 (ARVD2) and idiopathic ventricular fibrillation (Priori
et al., 2002). In RyR1, mutations can lead to several disorders,
including malignant hyperthermia (MH) (MacLennan and Phil-
lips, 1992) and central core disease (CCD) (Quane et al., 1993;
Zhang et al., 1993). Based on the crystal structure of the
RyR1 N-terminal region, it was found that disease mutations
are mostly found at interfaces between domains and are
capable of altering relative domain orientations (Kimlicka
et al., 2013). Although many mutations have been mapped
onto the RyR1 crystal structure, our high-resolution insights
into the corresponding region of RyR2 have been limited to
the very N-terminal domain (Lobo and Van Petegem, 2009).
Here, we describe the crystal structure of the N-terminal region
of RyR2, consisting of three domains (‘‘RyR2ABC’’). In contrast
with RyR1, this region contains an anion binding site that is the
target for disease mutations that cause CPVT. The results sug-
gest that anion binding affects relative domain orientations and
may regulate RyR2.l rights reserved
Figure 1. Overall Structure of the RyR2 N-Terminal Region
(A) Cartoon representation of mouse RyR2 residues 1–547 (RyR2ABC). Blue, domain A; green, domain B; red, domain C. Select secondary structure elements are
labeled.
(B) Superposition of RyR1ABC (gray) and RyR2ABC (colors).
(C) Thermal melting curves indicating thermal stability. The melting temperatures, obtained by taking the maxima of the first derivatives, are 48.0C ± 0C
(RyR1ABC), 43.1C ± 0.4C (RyR2ABC), and 42.3C ± 1.4C (RyR2ABC R420Q) (errors indicating SD of the mean). The RyR2ABC wild-type (WT) and mutant
melting curves show two transitions, but due to the shallow nature of the second transition, a melting temperature for this portion could not be obtained reliably.
See also Figure S1.
Structure
Structure of the RyR2 Anion Binding SiteRESULTS
Overall Structure of the RyR2 N-Terminal Region
We solved the structure of mouse RyR2 residues 1–547
(RyR2ABC) at 2.0 A˚ resolution. The structure consists of three
individual domains (A, B, and C) that form a compact arrange-
ment (Figure 1A; Figure S1 available online). Domains A and B
display a b-trefoil fold, whereas domain C forms an a-helical
bundle typical of armadillo repeats. Domain A contains an a helix,
previously observed for the structure of the individual domain
(Lobo and Van Petegem, 2009) and for RyR1ABC (Tung et al.,
2010), but in this case the helix was disordered, suggesting there
is some intrinsic flexibility to this secondary structure element.
The domains are held together by a number of ionic interactionsStructure 21, 1440(Table 1). In the corresponding RyR1ABC structure, ionic interac-
tions are also responsible for the compact domain arrangement,
and the overall domain orientations between the two isoforms
are similar (Figure 1B). We compared the thermal stability of
RyR1ABC and RyR2ABC via a thermofluor assay. The RyR2ABC
protein appeared less stable than RyR1ABC (1–536), with an
5C difference in melting temperature, although the melting
transition occurred later and was steeper (Figure 1C).
Despite the similarity in the overall domain arrangement, a
closer inspection of the domain-domain interactions reveals a
crucial difference. In RyR1, there is an ionic pair network consist-
ing of four residues that are located in all three domains (Table 1;
Figure 2A); Arg 283 (domain B) forms a salt bridge with
Asp61 (domain A), which also forms an ionic pair with Arg402–1449, August 6, 2013 ª2013 Elsevier Ltd All rights reserved 1441
Table 1. Interdomain Salt Bridges
Domains Involved Rabbit RyR1 Mouse RyR2
B-C Arg242-Glu481 Arg257–Glu492
B-C Arg221-Glu397 Arg 235–Glu412
B-A-C-A (network) Arg 283-Asp61–
Arg402–Glu40
Arg298–Asp 61 X
Arg 417 X Glu40
A–C Arg45–Asp447 Arg45–Asp 458
Ionic pairs between domains in RyR1ABC and RyR2ABC structures. ‘‘X’’
marks ionic pairs that do not exist in RyR2ABC.
Structure
Structure of the RyR2 Anion Binding Site(domain C), which finally forms a further salt bridge with Glu40
(domain A). Such networks of interactions are more stable than
individual pairs, and this is therefore a major stabilizing element
for the RyR1ABC structure. The latter three residues in the
network also form multiple hydrogen bonds with one another,
further adding to the stability. In RyR2, however, this network
is disrupted (Figure 2B). Although the four residues involved in
the network are conserved, there is a substitution of RyR1
His405 on domain C by Arg420 in RyR2. Instead of a four-residue
network, only a single ionic pair remains, formed by Arg298 and
Asp61, and all hydrogen bonds within the network are lost.
However, the ionic pair network seems to be replaced by a
chloride ion. It is coordinated by electrostatic interactions with
residues from domains B and C: Arg420, Arg298, and Arg276.
The hydroxyl group of Tyr125 is within 4.5 A˚, too far to create a
hydrogen bond, but the Tyr125 side chain forms a ‘‘lid’’ that
further shields the anion and its hydroxyl group hydrogen bonds
with the Arg420 side chain. Arg417, involved in the network in
RyR1, is near the chloride ion, but its positive guanidinium group
is pointing away. The chloride site is almost completely buried
(Figure 2C).
Chloride Can Be Exchanged
The RyR2ABC protein was purified in the presence of high KCl.
Chloride binding appeared essential for stability, as removal of
chloride prevented the protein from remaining soluble at con-
centrations required for crystal growth. The absence of an anion
would allow several positively charged arginines to be in prox-
imity, which destabilizes the domain-domain interactions.
Does the site also accommodate other anions? In order to
answer this question, we exchanged KCl with KBr, and the
concentrated protein remained stable in solution under these
conditions. We then grew RyR2ABC crystals in bromide and
obtained a 2.3 A˚ structure. Data were collected at the absorption
edge for bromide, allowing us to calculate anomalous difference
maps. An anomalous peak was visible up to 34 s (Figure 2D),
providing an unambiguous assignment for a bromide ion at the
anion binding site. As the ionic radius for bromide (1.82 A˚) is
only slightly larger than for chloride (1.67 A˚), it is not surprising
that it can bind to the same site. Bromide ions are not physiolog-
ically relevant, but the bromide anomalous signal confirms the
presence of a halide ion binding site. Since the KCl was
exchanged for KBr only at the end of the purification, this also
means that anion binding to this site is a reversible process.
Although the anion is buried and protected from solvent within
the structure, this shows that dynamic breathing motions allow
ion exchange.1442 Structure 21, 1440–1449, August 6, 2013 ª2013 Elsevier Ltd AlThe R420Q Disease Mutation Affects Chloride Binding
One of the arginines that coordinates the chloride ion, Arg420, is
the target for two disease mutations (R420Q and R420W). We
investigated the structure of the R420Q mutant, which has
been linked to CPVT (Medeiros-Domingo et al., 2009). In RyR1,
the corresponding residue is a histidine instead and no chloride
binding was detected. We therefore expected the R420Q muta-
tion to abolish the binding site and to re-establish the central
ionic pair network observed in RyR1.We solved the crystal struc-
ture of RyR2ABC R420Q at 2.15 A˚ resolution (Figure 3). As ex-
pected, no density was observed for a chloride. However, the
ionic pair network was not restored. More in particular, the
Arg417 side chain, which is involved in the network in RyR1 by
pairing up with Asp61 and Glu40, still does not pair up with either
residue in the R420Q mutant, despite the absence of the chlo-
ride. This seems to be due to the side chain of Tyr125, which
would sterically clash with Arg417 in its configuration necessary
for the salt bridges. Interestingly, both Tyr125 and Arg420
appear to be strongly conserved among all mammalian RyR2 se-
quences aswell as in some other species (Figure S2). The excep-
tion is RyR2 fromMyotis davidii, which does contain Arg420 but
not Tyr125. Overall, this suggests that the anion binding is
strongly conserved among mammalian RyR2s and may play a
functional role.
The absence of chloride in the R420Q structure removes a link
between domain C (Arg420) and domain B (Arg 276 and Arg298).
Although the local rearrangements around the chloride site are
small, the mutation seems to affect relative domain orientations.
Superposition based on domain C alone shows that the posi-
tions of domains A and B relative to domain C are changed;
main-chain atoms in domain A and B shift by as much as 1.4 A˚
(Figures 3B and 3C). These shifts seem to be the result of a tilting
around an axis near the domain B-C interface. As a result, the
shifts are almost invisible right next to the chloride binding site
and are largest further away. In contrast, the relative position
of domains A and B is unchanged (Figure 3D). We have previ-
ously observed that interdomain salt bridge mutations in RyR1
can cause similar relative domain reorientations. Altering domain
orientations thus seems to be a common theme with several
disease mutations in both RyR1 and RyR2.
Although no chloride was detected for the R420Q mutant, we
wondered whether there is still some residual affinity, resulting in
a lower occupancy of the anion binding site that could not be
detected in conventional difference maps. We therefore also
cocrystallized the R420Q mutant with KBr and kept a high con-
centration of KBr (500 mM) during the soak into cryoprotectant.
After creating an anomalous difference map, a peak was visible
at the anion binding site but only visible to 5.5 s compared to
34 s for wild-type, suggesting a much lower occupancy despite
the increased KBr concentration. The mutant therefore has a
reduced affinity for anions but can still bind them at much higher
concentrations.
Additional RyR2 Disease Mutations
Figure 4A shows the positions of the known disease mutations
that target the RyR2ABC domains. In total, 29 RyR2 mutations
can be mapped on the RyR2ABC structure, dispersed over 27
distinct sites, as two sites are the target for multiple mutations.
The Dexon3 is an abnormal mutation that ablates residuesl rights reserved
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Figure 2. Details of the Anion Binding Site
(A) Interdomain interaction area for RyR1ABC showing the salt-bridge network involving residues in all three domains. Black dashed lines indicate hydrogen
bonds between ionic pairs. Orange dashed lines indicate a salt bridge between Arg283 and Asp61 that is not formed by hydrogen bonds.
(B) The corresponding region in RyR2ABC. Domains are colored as in Figure 1. Fo  Fc density, contoured at 3 s, is shown for the chloride site. Dashed lines
indicate contacts with positively charged arginine atoms and a hydrogen bond between Tyr125 and Arg420. Two histidine residues in RyR1 are replaced by Arg
420 and Tyr125. This results in a disruption of the ionic pair network and the creation of a chloride binding site. Arg298 and Asp61 form a salt bridge that is not
mediated by hydrogen bonds.
(C) Surface representation of RyR2ABC, with the chloride ion shown as a black sphere. The chloride is inaccessible to solvent.
(D) Anomalous difference maps for the bromide-bound structure, contoured at 7 s (outer mesh) and 20 s (inner mesh). The peak is visible up to 34 s.
See also Figure S2.
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Structure of the RyR2 Anion Binding Site57–91, causing a severe form of CPVT (Bhuiyan et al., 2007; Mar-
jamaa et al., 2009; Medeiros-Domingo et al., 2009). The deletion
includes a b strand (b4) that is part of the b-trefoil fold of domain
A, but a crystal structure of RyR2ADexon3 showed that exon4, a
flexible stretch in wild-type RyR2A, can rescue this by inserting
itself into the b-trefoil core (Lobo et al., 2011). However, upon
creating the exon 3 deletion of RyR2ABC, we were unable to
purify the construct, as it was readily degraded and appeared
unstable. Several residues in exon 3 interact with domain B (Fig-
ure 4B). This includes Asp61, which forms a salt bridge with
Arg298 on domain B (Figure 2B). As the identities of amino
acid residues in exon 4 are all different (Lobo et al., 2011), the
contacts between domains A andBmediated by exon 3 residues
are very different. Our inability to obtain pure nondegraded
RyR2ABC Dexon3 suggests that the alternative contacts
involving exon 4 are significantly less stable.
In addition, we created a number of point mutants in RyR2ABC
that correspond to individual disease mutations. These include
the mutants L62F, F329L, T415R, R420Q, and L433P, and are
either located at intrasubunit domain interfaces or are buried
within individual domains (Figure 4A). All have been linked toStructure 21, 1440CPVT (Medeiros-Domingo et al., 2009), except for L433P, which
has been found to associate with ARVD2 (Tiso et al., 2001). With
the exception of R420Q, all mutant versions of RyR2ABC
behaved poorly and were heavily degraded upon extraction
and after the first two chromatography steps. This is in sharp
contrast with point mutations in RyR1ABC, where multiple muta-
tions destabilized the protein, but could still be purified (Kimlicka
et al., 2013). L62F is located within exon 3, at the interface
between domains A and B (Figure 4C). There is no space for a
bulkier Phe group, so domain rearrangements would be neces-
sary. F329 is completely buried within domain B, where it forms
part of a hydrophobic core that consists of several Leu, Ile, and a
Phe residues (Figure 4D). The F329L mutation thus introduces a
smaller hydrophobic side chain, reducing the packing and
destabilizing the folding of domain B. Thr415 is buried between
two a helices within domain C (Figure 4E). There is no space
for the much longer Arg side chain, so this residue would cause
misfolding of domain C. The L433Pmutation has previously been
shown to reduce the luminal Ca2+ threshold at which Ca2+
release terminates (Tang et al., 2012). Leu433 is completely
buried within domain C, where it is part of a hydrophobic core–1449, August 6, 2013 ª2013 Elsevier Ltd All rights reserved 1443
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Figure 3. Structure of the R420Q Disease Mutant
(A) Crystal structure of the R420Q disease mutant (gray) superposed on the WT RyR2ABC structure (colors). No chloride density was visible for the disease
mutant.
(B and C) Superposition of WT (colors) and R420Q RyR2ABC (white) based on domain C showing the relative positions of domains A (B) and B (C). Shifts in the
domain arrangement are indicated by arrows. Domains A and B are shifted relative to domain C.
(D) Superposition ofWT and R420Q based on domain A showing a near-perfect superposition of domain B, indicating the relative orientation of domain A versus B
is unchanged.
See also Figure S3.
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Structure of the RyR2 Anion Binding Site(Figure 4F). Mutation to a Pro has two effects: it affects the
hydrophobic packing, and being a helix breaker it can also
destabilize the a helix in domain C.
Putative Ligand Binding Sites
For the wild-type crystal structure, extra density was observed in
two areas near the interfaces of domains A and C and between
domains A, B, and C (Figure 5). These densities were attributed
to low molecular weight polyethylene glycol (PEG) molecules,
which were used as cryoprotectant. High molecular weight
(MW) PEG was used as a crystallization agent, but small
amounts of low MW PEG are often present as contaminant.
Using glycerol as cryo-protectant instead, some uninterpretable
density remained at these sites, likely corresponding to disor-
dered glycerol or partially occupied low MW PEG that could
not be modeled reliably. The cryoprotectants were only used
to soak existing crystals, and as expected did not cause any sig-
nificant rearrangements.1444 Structure 21, 1440–1449, August 6, 2013 ª2013 Elsevier Ltd AlBoth PEG molecules bind in very deep pockets. Pocket 1 is
located at the interface between domains A and C, whereas
pocket 2 is located primarily between domains B and C.
Although PEG molecules are not physiologically relevant, these
pockets may form ideal sites for developing small molecules
with higher affinity. Since many disease mutations seem to
destabilize domain-domain interactions, targeting molecules
to such pockets may stabilize the interactions and thus have
therapeutic potential.
DISCUSSION
RyRs form large tetrameric assemblies that release Ca2+ from
the SR or ER. Each subunit consists of many domains that
have individual functions (Van Petegem, 2012). Some form bind-
ing sites for auxiliary proteins or small molecule ligands, whereas
others couple conformational changes in the transmembrane
area to movements in the cytoplasmic head. The N-terminall rights reserved
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Figure 4. Additional RyR2 Disease Mutants
Domains are colored according to Figure 1.
(A) Mapping of known disease mutations on the RyR2ABC structure, with the target residues shown as black sticks. Exon 3 is shown in black cartoon
representation.
(B) Detail of several exon 3 residues (black) interacting with domain B.
(C–F) Details of the environments of four disease mutation target sites for which purification was attempted. The mutated residue is shown in black sticks. All four
caused destabilization of the protein, resulting in heavily degraded material. Shown are positions of L62F (C), F329L (D), T415R (E), and L433P (F).
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Structure of the RyR2 Anion Binding Sitearea of RyR1 and RyR2 was previously described as a ‘hot spot’
for disease mutations causing MH, CCD, CPVT and other condi-
tions. However, many more mutations are continuously found in
between the originally defined hot spots, especially for RyR1.
Previous crystallographic studies of the RyR1 N-terminal region
have shown that this area consists of three domains: two b-trefoil
domains (domains A and B) and an armadillo repeat domain
(domain C). They are located in the cytoplasmic area, forming
a continuous ring around the central four-fold symmetry axisStructure 21, 1440(Tung et al., 2010). Comparison of this area in closed and open
RyR1 cryo-EM maps shows that conformational changes in
the pore are allosterically coupled to the N-terminal region. A
plausible model suggests that channel opening results in the
disruption of favorable intersubunit interactions, an event that
requires an energetic penalty to be paid (Kimlicka et al., 2013).
As such, the N-terminal region would act as a brake on channel
opening, and energy through binding of external ligands
is required to open the channel. The N-terminal region of–1449, August 6, 2013 ª2013 Elsevier Ltd All rights reserved 1445
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Figure 5. PEG Binding Sites
(A) Surface representation of RyR2ABC, showing two
binding pockets for short polyethylene glycol molecules.
Coloring is according to Figure 1. Weighted 2Fo Fc density
is shown in black mesh, contoured at 1 s. The view is from
the ‘‘bottom’’ compared to Figure 1, as viewed from the
ER/SR lumen toward the cytosol.
(B) Details of the two binding pockets, showing all residues
within 4 A˚. The chloride ion (sphere, not within 4 A˚) is shown
for reference.
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Structure of the RyR2 Anion Binding Siteinositol-1,4,5-trisphosphate receptors (IP3Rs) shows a similar
arrangement of three domains (Lin et al., 2011; Seo et al.,
2012) and is also located within the cytoplasmic head near the
four-fold symmetry axis (Lin et al., 2011; Ludtke et al., 2011;
Seo et al., 2012).
The three mammalian RyR isoforms share a large amount of
sequence conservation (65%), but they differ strongly in their
functional properties, such as their sensitivity to various inhibi-
tory and activating ligands (Fill and Copello, 2002). Some of
these differences may be attributed to divergent regions, three
stretches within the sequence where the sequence conservation
is very low. However, it is likely that some of these differences
lie in the remaining >4,500 amino acids, despite their higher
sequence conservation. Although we were previously able to
crystallize the RyR1 N-terminal three domains, we wondered
whether there might be intrinsic differences in this region
between RyR1 and RyR2.1446 Structure 21, 1440–1449, August 6, 2013 ª2013 Elsevier Ltd All rights reservedOur insights into the RyR2 N-terminal region
were limited to the structure of the very N-termi-
nal domain (‘‘RyR2A’’) (Lobo and Van Petegem,
2009), which did not allow us to peer into the
interdomain contacts. In order to get more in-
sights into the cardiac ryanodine receptor, we
solved the crystal structure of mouse RyR2
(1–547), covering three N-terminal domains
(A–C). The structures of the individual domains
are very similar to those in the skeletal muscle
isoform (RyR1), but, surprisingly, the interactions
between these domains are very different. In
RyR1, the three domains are kept in a compact
conformation through a series of salt bridge inter-
actions. This includes a central ion pair network
involving four charged residues that are spread
out over the three domains. Networks of ionic
pairs are more stabilizing than individual ionic
pairs because of the reduced desolvation pen-
alties (Karshikoff and Ladenstein, 2001). As
such, this network is a great contributor to the
overall stability of the domain interactions. In
RyR2ABC, however, this salt bridge network is
disrupted by the addition of a chloride ion that
occupies the space where the three domains
meet and shields electrostatic repulsion created
by several arginine residues. Although all four
residues involved in the salt bridge network in
RyR1 are conserved in RyR2, it seems to be
specifically disrupted because of two mutations:H420R and H125Y (RyR2 numbering). Arg420 provides an extra
ligand for the chloride ion, whereas Tyr125 forms a lid, prevent-
ing Arg417 to form salt bridges with Asp61 and Glu40. In addi-
tion, Tyr125 hydrogen bonds with the Arg420 side chain. Both
Arg420 and Tyr125 are strongly conserved in mammalian RyR2
sequences, suggesting they are both required for chloride
binding.
RyRs are complex macromolecules that open and close in
response to a range of stimuli. Previously, it has been reported
that the activity of RyRs can be influenced by anions (Fruen
et al., 1994, 1996). For RyR2, tritiated ryanodine binding was
found to be higher in 0.25M KCl versus 0.25M KMes (Liu et al.,
1998), suggesting that chloride can increase the activity of
RyR2. However, in another study chloride was found to have little
or no effect on RyR2 Ca2+ release, and the effect likely depends
on the extraction conditions (Fruen et al., 1996). The ability of
chloride to modulate RyR2 may be due to binding to the RyR2
Structure
Structure of the RyR2 Anion Binding SiteN-terminal region. Removal of chloride has a large effect on the
stability of the RyR2ABC protein, as it allows for repulsive inter-
actions between arginines on different domains. Therefore, it is
likely that removal or addition of chloride to this site has a func-
tional consequence. The activity of RyR1 is also dependent on
chloride, yet it does not contain a chloride site within the N-ter-
minal region. Chloride dependence of activity may therefore be
a complex event involving multiple sites, and the previously
reported effect of chloride on RyR2 could therefore be the result
of multiple sites.
Could the chloride binding within a physiological setting be
a dynamic event that is regulated, or is the chloride binding
‘‘structural’’ (i.e., always bound)? The cytosolic concentration
of chloride is in the lowmM range, so the answer to this question
depends on the inherent affinity. A high affinity would mean the
site is always occupied, whereas an affinity in the low mM range
would imply that RyR2 may exist in both chloride bound and
unbound conformations in physiological settings. Although
chloride could be removed from RyR2ABC through dialysis,
the protein readily precipitated at concentrations required to
detect binding through, for example, isothermal titration calorim-
etry. As a result, wewere unable to directly determine the affinity.
We previously analyzed the effect of disease mutations on the
structure of RyR1ABC (Kimlicka et al., 2013). Disease mutations
that abolished interdomain salt bridges (R402G, D61N, and
R45C in rabbit RyR1) resulted in relative domain reorientations.
As the RyR2ABC protein could not be concentrated in the
absence of chloride or bromide, we were unable to assess
the effect of chloride removal on the structure. Removal of the
chloride would not only take away favorable interactions, but it
would also allow repulsive interactions between several arginine
residues to happen. These would likely result in altered domain
orientations. It is not clear at this point which of the two states
(chloride bound or chloride-free) would correspond to an acti-
vated state of the N-terminal region.
We expressed several disease mutant forms of RyR2ABC.
However, with the exception of R420Q, all mutants degraded
readily or showed signs of aggregation. It is possible that some
of the RyR2ABC disease mutations perturb the structures of
the individual domains to a level that affects chloride binding,
resulting again in repulsive interactions between the exposed
arginine residues that further destabilize the protein.
Two RyR2 disease mutations directly target the chloride bind-
ing site: R420Q and R420W. R420W has previously been shown
to reduce the threshold for Ca2+ release termination (Tang et al.,
2012). We analyzed the structure of R420Q and found that
chloride binding was abolished. Using the anomalous signal of
bromide, we could detect some residual binding of an anion at
very high concentrations, but the occupancy was clearly much
lower. In addition, the small perturbations around the chloride
binding site resulted in relative domain reorientations as a result
of tilting around an axis near the domain-domain interfaces.
Domains A and B maintain the same relative orientation, but
both are displaced relative to domain C, with maximum shifts
1.4 A˚ furthest away from the tilting axis. These observations
are based on an isolated fragment, and the extent of conforma-
tional changes may be different in full-length RyR2. However,
relative domain reorientations seem to become a common
theme in activation of calcium release channels. IP3 receptorsStructure 21, 1440are activated by the ligand IP3, which binds to a pocket between
domains B andC. Interestingly, the binding also causes a relative
reorientation of the N-terminal domains (Lin et al., 2011; Seo
et al., 2012). Thus, what is a regulatory event in IP3Rs is a perma-
nent event in several disease mutant forms of both RyR1 (Kim-
licka et al., 2013) and RyR2. The altered domain orientations
likely destabilize the intersubunit interface, resulting in facilitated
channel opening (Kimlicka et al., 2013; Seo et al., 2012).
EXPERIMENTAL PROCEDURES
Cloning, Purification, and Crystallization of RyR2 N-Terminal Region
Mouse RyR2 1–547 (RyR2ABC) was cloned and expressed as previously
described for the RyR1 constructs (Tung et al., 2010). All point mutants were
prepared using the QuikChange protocol (Stratagene). The delta exon 3
variant of RyR2ABC was cloned using a full-length construct as a template
(gift from the laboratory of Wayne Chen, University of Calgary). The proteins
were purified similarly to the corresponding RyR1 construct, except that
following a ResourceQ column (GE Healthcare), they were run on a Phenyl
Sepharose column (GE Healthcare) in 10 mM Tris-Cl (pH 8.0) and 14 mM
b-ME, with a gradient from 50 to 1,500 mM KCl. The samples were then run
on a preparative Superdex 200.
Protein crystals were produced by exchanging the samples to 250 mM KCl,
10 mMNa-HEPES (pH 7.4), and 5 mM dithiothreitol and concentrating them to
10 mg/ml using 10,000 MW cutoff concentrators (Amicon, Millipore). All crys-
tals were obtained at room temperature using the hanging drop method. Wild-
type proteins were crystallized in 0.1 M Tris (pH 8.15), 5%–10%PEG3350, and
1%EtOH. Bromide-bound protein and the R420Qmutant crystallized in similar
conditions, except that seeding using wild-type crystals was necessary. All
crystals were flash-frozen in the corresponding mother liquor containing
40% PEG200 or 35% glycerol. Crystals in complex with bromide were
obtained by exchanging KCl for KBr through dialysis.
Data Collection, Structure Solution, and Refinement
Data were collected at beamlines 08ID of the Canadian Light Source (CLS,
Saskatoon) and 9-2 of the Stanford Synchrotron Radiation Laboratory
(SSRL, Menlo Park). The data were processed using XDS (Kabsch, 2010).
The RyR2ABC wild-type structure was solved using molecular replacement
implemented in Phaser (McCoy et al., 2007) with the individual domains of
RyR1ABC structure as search models. An improved structure was then gener-
ated through autobuilding using Arp/wArp (Langer et al., 2008). Refinement
consisted of successive rounds of manual modeling in COOT (Emsley and
Cowtan, 2004) and refinement in REFMAC5 (Murshudov et al., 1997) with
translation, libration, and screw-rotation restraints applied to individual
domains. The RyR2ABCR420Qmutant structure was solved using the individ-
ual domains of RyR2ABC as search models and refined as described for
wild-type RyR2ABC. Data collection and refinement statistics are available
in Table 2. Anomalous maps for the bromide-grown crystal were obtained
using calculated phases from the RyR2ABC structure and using anomalous
differences from a data set collected at the peak absorption of bromide.
Fluorescence-Based Thermal Shift Assays
Protein melting curves were measured using thermofluor assays (Nettleship
et al., 2008). A total of 10 ml of 1 mg/ml protein was mixed into a 50 ml solution
containing 13 SYPRO orange dye (Invitrogen), 150 mM KCl, 10 mM HEPES
(pH 7.4), and 14 mM b-mercaptoethanol. Melting curves were obtained using
a DNA Engine Opticon 2 real-time PCR machine (Bio-Rad), using the SYBR
green filter option. The temperature was increased from 25C to 95C with
0.5C steps, with the temperature held constant for 15 s before data acquisi-
tion. Melting temperatures were obtained by taking the maxima of the first
derivatives of the melting curves.
ACCESSION NUMBERS
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Table 2. Crystallographic Parameters
WT R420Q
Data Collection
Space group P42212 P42212
Cell dimensions
a, b, c (A˚) 78.04, 78.04, 248.38 78.22, 78.22, 248.65
a, b, g () 90, 90, 90 90, 90, 90
Resolution (A˚) 50-2.0 (2.05-2.0) 50-2.15 (2.27-2.15)
Rsym or Rmerge
a 9.1 (173.2) 10.3 (188.8)
I/sI 15.6 (2.0) 20.2 (2.4)
Completeness (%) 99.6 (99.9) 99.7 (99.7)
Redundancy 5.7 (5.8) 14.3 (14.7)
Refinement
Resolution (A˚) 50-2.0 50-2.15
No. reflections 50190 40856
Rwork/Rfree 22.03/25.11 22.83/26.29
No. of atoms
Protein 3564 3553
Ligand/ion 18 6
Water 83 64
B-factors
Protein 45.4 21.6
Ligand/ion 51.9 58.5
Water 44.6 23.1
Root-mean-square deviations
Bond lengths (A˚) 0.021 0.013
Bond angles () 1.809 1.430
Values in parentheses are for the highest-resolution shell.
aMerging R factor:
Rmerge =
X
hkl
X
i
IiðhklÞ  IðhklÞ
=
X
hkl
X
i
IiðhklÞ:
Structure
Structure of the RyR2 Anion Binding SiteRCSB Protein Data Bank with the accession numbers 4L4H and 4L4I,
respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at http://dx.doi.org/10.1016/j.str.2013.06.012.
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